Hormonal contraceptives and breast cancer risk in BRCA1 carriers
HQ Team January 17, 2025: A study has found a significant association between the use of hormonal contraceptives and an increased risk of.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team January 17, 2025: A study has found a significant association between the use of hormonal contraceptives and an increased risk of.
Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid.
HQ Team December 30, 2024: Researchers have identified a strong link between plastics and the rising incidence of breast cancer. Breast cancer has.
Bharti Jayshankar December 16, 2024: Researchers at the Rajiv Gandhi Biotechnology Centre, Kerala, delving into the molecular mechanisms of tumorigenesis by BRCA1 gene,.
Bharti Jayshankar December 13, 2024: AstraZeneca and Merck have announced long-term results from the OlympiA Phase 3 trial, showing that Lynparza (olaparib) significantly.
Bharti Jayshankar November 30, 2024: A study done by the University of Texas MD Anderson Cancer Center revealed that some breast cells in healthy.
AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.
Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an.
Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of.
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.